| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
To develop such a method to measure β-cell mass (BCM), we took advantage of the previously reported non-invasive detection of glucagon-like peptide-1 receptor using radiolabeled ligand. GLP-1R is highly expressed in rodent and human pancreatic β cells. We selected Exendin-4 (Ex4), a stable agonist of GLP-1R, as the mother compound and bound 111In to it using diethylenetriamine pentaacetic acid (DTPA) as a chelating moiety. 111In-DTPA-Ex4 produced as a probe for single photon emission computed tomography (SPECT) showed a high affinity for GLP-1R in vitro. We have performed SPECT imaging in normal and β-cell loss mice and determined a correlation between the uptake of 111In-DTPA-Ex4 in the pancreas and BCM to investigate the potential for the in vivo quantification of BCM by SPECT with 111In-DTPA-Ex4. This imaging technique would be promising tools for islet transplantation research.
|
